Systemic Lupus Erythematosus Exercise Program

Systemic Lupus Erythematosus Clinical Trial

— SLEEP  

Official title:

Internet-based Supervised Exercise Program in Systemic Lupus Erythematosus: A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03942718
• Other study ID #: UniversityMedCntrMainz
• Status: Completed
• Phase: N/A
• Start date: March 21, 2018
• Est. completion date: August 1, 2020

Study information

• Verified date: November 2022
• Source: University Medical Center Mainz
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study is a randomized controlled trial to assess the effect of an individualized supervised exercise program in patients with systemic lupus erythematosus (SLE) compared to treatment-as-usual (TAU).

Description:

The aim of this study is to evaluate the effect of a 12-week individualized exercise program in subjects with SLE in comparison to treatment-as-usual therapy. Several previous studies showed that exercise leads to various benefits in treating SLE, including enhanced aerobic capacity, reduced symptoms of depression and fatigue. Moreover, it has been shown that exercise is well tolerated and does not impair disease activity in SLE negatively. Here, the effects of an individual internet-based exercise therapy for 12 weeks will be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 1, 2020
• Est. primary completion date: April 25, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Positive ANA-titer (= 1:80) or Anti-dsDNA (= 200 IU/ml) or Highly avid-dsDNA autoantibody (= 30 IU/ml)

• Stable immunosuppressive therapy more than 30 days before beginning of the study with steroid (0-20 mg/day) or other immunosuppressive medication like Hydroxchloroquin, Chloroquin, Azathioprin, Methotrexat, Mycophenolatmofetil, Cyclosporin, Belimumab, Rituximab

Exclusion Criteria:

• Pregnancy, Active lupus nephritits, Physical activity more than two times a week

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

Intervention

Other:
• Exercise
Participants will obtain an individualized exercise program based on entrance examination on treadmill.

Locations

Country	Name	City	State
Germany	UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz I. Medizinische Klinik und Poliklinik	Mainz	Rheinland-Pfalz

Sponsors (2)

Lead Sponsor	Collaborator
University Medical Center Mainz	Johannes Gutenberg University Mainz

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak oxygen uptake (VO2peak)	Change of VO2peak after 12-weeks compared to baseline.	12-weeks
Secondary	Fatigue Scale for Motor and Cognitive Functions (FSMC)	Change of FSMC score after 12-weeks compared to baseline. The FSMC consists of 20 items (five-point Likert scale, from "absolutely agree" to "absolutely disagree") to assess cognitive fatigue (10 items) and motor fatigue (10 items). The summed scores for cognitive and motor fatigue result in the sum score. A cut-off value of 43 indicates mild fatigue, whereas higher values are associated with moderate fatigue (=53) or severe fatigue (=63).	12-weeks
Secondary	Beck Depression Inventar (BDI)	Change of BDI score after 12-weeks compared to baseline to measure the severity of depression. The BDI questionnaire consists of 21 sets of statements. Each set consists of 4 statements which are ranked in terms of severity from 0 to 3. The sum of the item scores (range 0-63) indicates the severity of depression. The standardized scale is: 0-8: no depression. 9-13: minimal depression. 14-19: mild depression. 20-28: moderate depression. 29-63: severe depression.	12-weeks
Secondary	Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)	The Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) - Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (SELENA-SLEDAI) will be used to measure the disease activity. The index consist of 24 items including clinical and laboratory variables to measure disease activity within the previous 10 days. The maximum score is 105. SLEDAI scores >3 indicate a mild or moderate flare, SLEDAI =12 indicate a severe flare.	12-weeks
Secondary	Disease Activity Score 28 (DAS 28)	Change of DAS 28 score after 12-weeks compared to baseline. The DAS 28 score indicates rheumatoid arthritis disease activity and treatment response. The score composes of 4 measures including the number of swollen/tender joints, C reactive protein and patients health assessment. A total score is calculated using the DAS 28 formula. Values range from 2.0 to 10, whereas higher values indicate higher disease activity.	12-weeks
Secondary	Work Ability Index (WAI)	The WAI self-assessment questionnaire will be used to assess the workability of the patients. The questionnaire covers six dimensions including current workability, as well as past 2 year estimation among others. The answers have different scores, which are summed to a total score, leading to four categories. 7-27 points indicate bad, 28-36 points moderate, 37-43 good, and 44-49 points very good workability.	12-weeks
Secondary	Circulating, cell-free Deoxyribonucleic acid (CfDNA)	The concentration of cfDNA (ng/ml) will be measured during and after acute exercise at baseline and after 12-weeks exercise intervention using quantitative PCR. Compared to healthy subjects SLE patients show higher cfDNA plasma levels.	12-weeks
Secondary	Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI)	Change of score on RCLASI after 12-weeks compared to baseline. The RCLASI scoring system includes the RCLASI Activity Score to measure the activity of skin lesions, and the RCLASE Damage Score to measure the damage of skin lesions in patients with discoid lupus erythematosus and cutaneous lupus erythematosus. The score is used as a follow-up parameter for the Lupus activity of the skin. It was also shown that RCLASI correlates well with the physicians and patients global assessment of disease activity.	12-weeks
Secondary	Extra cellular vesicles (EVs)	The relative amount of EV subpopulations will be analyzed before and after acute exercise, as well as after 12-weeks of exercise intervention using bead isolation and or size exclusion chromatography followed by protein marker characterization.	12-weeks
Secondary	Autoantibodies	Change of antinuclear antibodies (ANA) titer after 12-weeks of exercise intervention compared to baseline (standard value =1:80).	12-weeks
Secondary	Ventilatory threshold (VT)	Change of VT after 12-weeks compared to baseline.	12-weeks
Secondary	Muscle mass	Change of muscle mass after 12-weeks compared to baseline. Muscle mass will be measured in absolute mass [kg] including internal organs using bioelectrical impedance analysis (InBody 3.0 Body composition analyzer).	12-weeks
Secondary	Chair-Stand-Test (CST)	Change of CST after 12-weeks compared to baseline.	12-weeks